EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antisense Oligonucleotides: Technological Advances, Clinical Progress, and Expanding Therapeutic Frontiers

Liping Xu, Huaqun Zhang iD, Bingchen Jiang, Yuanying Jiang, Hui Lu iD

Pharmaceutics · 04.04.2026 · 18 (4) · 446

DOI: 10.3390/pharmaceutics18040446 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 04.04.2026. Verfasst von Liping Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200331, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 169 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antisense oligonucleotides (ASOs) are emerging therapeutic agents that modulate gene expression at the RNA level, offering distinct therapeutic advantages over conventional small-molecule drugs and biologics. By directly targeting RNA, ASOs expand the spectrum of druggable targets to include those previously considered “undruggable”, and enable shorter development timelines with improved research and development efficiency. These attributes position ASOs as a highly promising platform for precision and personalized medicine. Recent advances in chemical modification strategies and delivery technologies have markedly accelerated their clinical translation. This review systematically examines the technological evolution of ASO therapeutics, detailing their mechanisms of action, key chemical modification strategies, and advanced delivery systems. It also provides a comprehensive overview of the current global clinical landscape, including approved drugs, discontinued candidates, and ongoing clinical trials. Finally, this review discusses the major challenges facing the field and outlines future directions, with the aim of informing subsequent basic research and clinical development efforts.

Schlagwörter

Stichwörter der Autor:innen

RNA-targeted therapeuticsantisense oligonucleotideschemical modificationprecision medicine

Autor:innen und Institutionen

  • Department of Pharmacy, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200331, China.
  • Department of Chemistry and Biochemistry, The Ohio State University, Columbus, OH 43210, USA.
  • Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai 200071, China.
  • Key Laboratory of Pathogen-Host Interaction, Ministry of Education, School of Medicine, Tongji University, Shanghai 200331, China.

ORCID-Profile: Huaqun Zhang, Hui Lu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Xu, L., Zhang, H., Jiang, B., Jiang, Y., & Lu, H. (2026). Antisense Oligonucleotides: Technological Advances, Clinical Progress, and Expanding Therapeutic Frontiers. Pharmaceutics, 18(4), 446. https://doi.org/10.3390/pharmaceutics18040446

Vancouver

Xu L, Zhang H, Jiang B, Jiang Y, Lu H. Antisense Oligonucleotides: Technological Advances, Clinical Progress, and Expanding Therapeutic Frontiers. Pharmaceutics. 2026;18(4):446. doi:10.3390/pharmaceutics18040446

BibTeX
@article{Xu2026,
  author = {Xu, Liping and Zhang, Huaqun and Jiang, Bingchen and Jiang, Yuanying and Lu, Hui},
  title = {Antisense Oligonucleotides: Technological Advances, Clinical Progress, and Expanding Therapeutic Frontiers},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {4},
  pages = {446},
  doi = {10.3390/pharmaceutics18040446}
}
Kostenlos starten →